Research on antibodies and their uses. Covers engineered antitoxin antibodies, long-lasting immunity, monoclonal therapies, and antiviral T cells.
Researchers discovered nine genes in S. mansoni's autophagy pathway inhibited by the primate's immune system, preventing parasite multiplication and contaminating the host. The study suggests a potential novel therapy and vaccine against schistosomiasis.
Researchers discovered that IgA and IgG antibodies regulate immune responses against endometrial cancer, improving outcomes when tumor cells express the antibody receptor pIgR. The study suggests new therapies targeting B cells or combinations with T-cell immunotherapies for enhanced efficacy.
A unique Irish study found that previous COVID-19 infection and age are associated with lower antibody levels six months after vaccination. The research highlights the importance of boosting vaccinations for vulnerable populations like nursing home residents.
A case series found that a fourth dose of an mRNA-based vaccine increases antispike IgG titers in kidney transplant recipients with weak serologic response after three doses. The researchers noted no safety concerns with the additional dose and suggested its use for such patients.
The study investigated the antibody response to 2 or 3 doses of the BioNTech-Pfizer vaccine in patients with solid tumors treated with anticancer agents. The researchers found that higher antibody levels were associated with better immune response and reduced risk of severe COVID-19.
A new study found that COVID-19 vaccination during pregnancy elicits high levels of antibodies in both mother and baby, regardless of when it occurs. The research suggests that pregnant women should not delay vaccination until late pregnancy, as it is likely to be beneficial for themselves and their babies.
Researchers identified antibodies targeting conserved sites on the spike protein, showing promise against future variants. Antibodies from vaccinated individuals retained some activity, while those with prior infection had reduced effectiveness.
The SARS-CoV-2 Alpha variant adapted to avoid triggering the innate immune response by increasing expression of antagonism proteins, which disable the body's first line of defense. This allows the virus to replicate under the radar in early stages of infection, significantly increasing its chances of infecting a person.
Despite receiving three vaccinations, kidney transplant patients have inadequate cellular and humoral protection against SARS-CoV-2, with around 90% showing little to no protection. Researchers are now investigating the efficacy and safety of a human antibody cocktail in these patients.
A COVID-19 antibody survey in Sierra Leone found significant underreporting of cases and low vaccination rates, posing a risk to populations with limited immunity. The study's findings call for rapid vaccine deployments and support for intellectual property waivers to address the pandemic's progression.
The Lancet infographic reviews COVID-19 diagnostic tests, highlighting their strengths and limitations. The study suggests that improved test accuracy could aid in pandemic control measures.
A new study suggests that breakthrough infections generate 'super immunity' to COVID-19, providing a robust immune response against the delta variant and potentially other variants. The study found that antibodies generated from breakthrough cases were 1,000% more effective than those from vaccinated individuals.
Researchers have discovered unique antibody-like proteins from sharks that can prevent the COVID-19 virus and its variants from infecting human cells. These shark-derived protein 'VNARs' are a promising new tool in the fight against SARS-CoV-2, with potential applications for future coronavirus outbreaks.
Research from Queen Mary University of London and Cardiff University found that certain MS treatments can reduce Covid-19 vaccine effectiveness in people with MS. The largest peer-reviewed study on the topic provides high-quality evidence to inform clinicians' guidance on treatment options.
Scientists have developed a fusion protein that successfully blocks replication of SARS-CoV-2 and related viruses in cell culture tests. The protein combines ACE2 with human antibody fragments, providing reliable protection against future mutations.
A study published in CMAJ found that hospital health care workers in Quebec had high seroprevalence of SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic. The highest rates were reported in hospitals with outbreaks, particularly those from older facilities.
Researchers found that a combination of natural infection and vaccination produces maximally potent antibodies against COVID-19. The study suggests that repeated exposures to the spike protein can improve the immune system's ability to produce high-quality antibodies against variants.
A study published in Journal of Biological Rhythms found that antibody levels are higher when healthcare workers received the SARS-CoV-2 vaccine in the afternoon. The study suggests that circadian rhythms may play a role in regulating immune responses to COVID-19 vaccination.
Researchers have identified hundreds of tiny llama antibodies called nanobodies that target the SARS-CoV-2 spike protein, which current therapies do not address. Combining these nanobodies into cocktails could create potent treatments against new variants, including Omicron.
Researchers report that combining infection and vaccination produces high-quality antibodies effective against COVID-19 variants. The study found that prior-infected individuals who received a vaccine had potent antibodies against new variants, contrary to previous findings suggesting reduced potency.
Researchers have discovered miniature antibodies derived from llamas that can neutralize SARS-CoV-2 and its variants, including Delta and Omicron. The nanobodies' small size allows them to access hard-to-reach spots on the virus, making them a potential treatment against future variants.
A recent study published in PLOS Pathogens found that the COVID-19 Delta variant may have a reduced ability to be neutralized by vaccines. The researchers analyzed serum samples from vaccinated individuals and found that the Delta variant was more effective at evading vaccine-induced immunity than other variants, such as Beta and Alpha.
Researchers at the University of Toronto have identified FAM72A as a crucial gene in antibody development, enabling high-quality antibodies by facilitating AID's effect. The findings also suggest that increased levels of FAM72A could spur cancer development and progression.
Previous antibody responses to harmless coronaviruses contribute to SARS-CoV-2 immunity, reducing infection severity and hospitalization rates. Researchers found that people with strong immune responses to other human coronaviruses have some protection against SARS-CoV-2 infection.
A study found that individuals under 65 had higher antibody levels than those over 65, with women outperforming men. However, by six months post-vaccination, antibody levels dropped significantly for everyone in the study group.
Research team discovered mRNA vaccines induce antibodies recognizing Spike and N protein fragments, potentially leading to misclassified breakthrough infections. The study suggests using multiple viral antigens for accurate detection of vaccine effectiveness.
A new study by Montefiore Einstein Cancer Center investigators found that a COVID-19 booster shot helps most cancer patients with no immune response after two-dose vaccination, significantly increasing antibody levels. The study also shows that all cancer patients benefit from vaccination, particularly those with blood cancer.
Scientists harness higher-order protein catenation to create complexed proteins with potential as artificial antibodies. The new method enables the synthesis of protein [n]catenanes, which show improved binding affinity and prolonged serum half-life.
PKU researchers harness higher order protein catenation to create complexed topological proteins, leading to the synthesis of artificial antibodies with enhanced affinity and prolonged serum half-life. The study successfully expands toolkits for protein entangling motifs, promoting advanced protein therapeutics.
Researchers from the University of Copenhagen have discovered that naturally acquired immunity to malaria works differently than immunity following vaccination. The immune system uses natural killer cells to fight the parasite, which is more tailored to the disease than other typical infections.
Researchers investigated the impact of mRNA vaccines on dialysis patients' immunity against Sars-Cov-2 variants. They found that while many produce reactive T cells, protective antibodies are formed less frequently. This immunological memory can be strengthened through vaccination and repeated contact with the pathogen.
A study published in JAMA Pediatrics found that mothers with disease-acquired immunity and those with vaccine-immunity produced high levels of antibodies in their breast milk, providing neutralization against SARS-CoV-2. The antibodies, including IgA and IgG, existed for three months after infection or vaccination.
A study of 77 lactating parents found a higher prevalence of anti-SARS-CoV-2 antibodies in breast milk among unvaccinated mothers, suggesting potential protection against COVID-19. The study also identified a link between vaccine-induced immunity and increased neutralizing activity in human milk.
Virginia Tech researchers have developed a miniature optical fiber treatment device that delivers cancer immunotherapeutic antibodies while monitoring tumor impedance to track treatment efficacy. The device elicits sustained anti-tumor immunity with complete tumor shrinkage in multiple tumor models.
Researchers found that older individuals produce higher levels of protective antibodies after infection or vaccination, providing better defense against emerging variants. Antibodies from infected individuals 50+ years old reacted strongly to the Delta variant, outperforming those from vaccinated adults under 50.
Researchers aim to make drug purification more efficient and scalable by understanding unwanted element interactions. They explored ligand-surface interactions using NMR spectroscopy and simulations.
Researchers have detected antibodies primarily made in response to mucous membrane infections, not typically thought of as a blood and liver infection, in study participants with malaria. The discovery provides new insight into the human body's response to malaria and may help identify new ways to treat or develop vaccines.
Researchers at Duke University and UNC-Chapel Hill have identified a new antibody that can block infections and minimize symptoms against a broad array of coronaviruses, including SARS-CoV-1 and SARS-CoV-2. The antibody was tested in animal models and found to be effective in protecting mice against developing severe lung symptoms.
Researchers at Johns Hopkins Medicine found that antibody levels against SARS-CoV-2 stay higher in people who were infected by the virus and then received protection from mRNA vaccine compared to those who only got vaccinated. A longer interval between virus exposure and first vaccine dose may enhance antibody response.
A Brazilian study demonstrates that a hyperimmune serum consisting of purified antibody fragments produced in horses can be an efficient approach to combat covid-19. The neutralizing activity of the sera has been proved to be high against the P.1 (Gamma) and P.2 variants, improving animal clinical conditions in hamsters.
Researchers developed a novel sensor that can detect SARS-CoV-2 proteins without antibodies, giving results within minutes. The technology enables rapid diagnostics for Covid-19 and future pandemics, reducing economic loss.
Cadmium exposure has been linked to an increased risk of developing allergies, particularly asthma, in children. Researchers found that gut bacteria over-produce an enzyme degrading vitamin D after cadmium ingestion, mimicking a deficiency, leading to enhanced allergic reactions.
Researchers discovered that a lower dose of the first shot, followed by a full-dose booster, significantly improved SARS-CoV-2 vaccine potency in mice. This approach, which involves an extended prime-boost interval, may lead to more robust and durable immune responses.
A new study found that COVID-19 can trigger severe psychiatric symptoms in adolescents, with anti-neural antibodies playing a potential role. Two patients with mild/asymptomatic COVID developed suicidal thoughts and paranoid fears, while another patient without prior psychiatric history recovered fully after treatment.
A study of young Swedish adults found that over one in four had SARS-CoV-2-specific antibodies, but fewer had measurable levels of memory B and T cells compared to other age groups. The researchers will continue to study long COVID and vaccination effects on immunity.
A new study from Karolinska Institutet finds that two vaccine doses increase antibody levels in the airways after COVID-19, while a second dose after recovery also boosts levels. The results highlight the importance of completing vaccination with a second dose to achieve optimal immune responses and reduce transmission.
A new study published in Science Translational Medicine found that male placentas have increased immune activation and receive fewer anti-COVID antibodies from their mothers. This may help protect male fetuses but pose risks to the fetus and child.
Patients with multiple myeloma often mount a poor antibody response to COVID-19 vaccines and have a weak T cell response, underscoring the need for booster vaccination and safety precautions. Researchers found that these patients are at high risk of severe COVID-19 infection.
Researchers will focus on understanding the disease, identifying B cell characteristics and plasma cells that create attacking antibodies. The study aims to enhance knowledge of SLE pathogenesis and differences in clinical manifestations, outcomes, and therapeutic responses.
A study by Northwestern University scientists has shown that coronavirus vaccines and prior infections can provide broad immunity against other, similar coronaviruses. The findings build a rationale for universal coronavirus vaccines.
A team of scientists has found that IgA antibodies, a natural defense substance in the human body, can limit the fitness of benign bacteria in the intestine. This discovery helps maintain a delicate balance between the human organism and the intestinal flora.
Breast milk from Mennonite moms on farms contains higher concentrations of IgA antibodies against food allergens and bacteria associated with farm animals. Babies born to these mothers show reduced rates of atopic diseases, suggesting a protective factor passed on through breast milk.
Researchers found that asymptomatic patients may not produce significant IgG antibodies, but rather a different kind of antibody count that can indicate disease severity. The study suggests using the ratio of these two counts as a marker to determine if a person has had COVID-19.
Patients with strong antibody responses against SARS-CoV-2 had low viral RNA levels and survived the illness. The study supports personalized treatment with exogenous antibodies for those with absent or low endogenous antibodies levels.
A study published in JAMA Oncology found that the type of cancer treatment affects the vaccine response, with chemotherapy resulting in lower antibody levels. Vaccination is still recommended for cancer patients, but optimal protection requires ongoing measures.
Pediatric transplant recipients have a more robust immune response to COVID-19 vaccines, achieving higher antibody levels after two doses compared to adult counterparts. This study suggests that the standard two-dose regimen may be safe and effective in pediatric transplant recipients.
Researchers at Uppsala University found that allergic stimulation activates mast cell precursor cells, which can produce cytokine IL-13 contributing to asthma development. This challenges the idea that only mature immune cells are involved in immune reactions.
Researchers at the University at Buffalo have developed a new treatment that pairs essential proteins with lysophosphatidylserine to build immune tolerance and prevent antibody development, potentially treating autoimmune disorders and allergies.
Researchers developed an Internet information system, virusMED, to provide a comprehensive picture of viruses' most important regions. The database contains over 800 strains from 75 different families, including SARS-CoV-2, influenza, Ebola, and HIV-1, enabling scientists to respond quickly and effectively against the next pathogen.
Researchers identified five specific mutations prevalent in Delta Plus infections compared to Delta, highlighting the need for expanded antiviral tools. The findings provide clues on how the virus mutates and evade antibodies produced from previous COVID-19 infections or vaccinations.